Alterome Therapeutics, Inc.

Alterome Therapeutics Initiates Phase 1 Trial of Novel Pan-KRAS Inhibitor ALTA3263 for Advanced Solid Tumors

2 months ago

• Alterome Therapeutics has dosed the first patient in a Phase 1/1b trial of ALTA3263, a novel oral pan-KRAS inhibitor designed to target over 90% of KRAS mutations in advanced solid tumors. • ALTA3263 uniquely inhibits both the "ON" and "OFF" states of KRAS, potentially addressing highly prevalent mutations like G12D and G12V that exist predominantly in the ON-state and remain a significant unmet medical need. • The open-label study will evaluate safety, tolerability, pharmacokinetics, and preliminary clinical activity in adults with advanced unresectable or metastatic solid tumors harboring KRAS mutations, which affect over 20% of metastatic cancer patients.